[Potential antiviral therapeutics for 2019 Novel Coronavirus]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004.
[Article in Chinese]

Abstract

The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.

2019新型冠状病毒(2019-nCoV)是武汉不明原因肺炎的致病原。2019-nCoV在遗传学上与一种蝙蝠来源的新型冠状病毒比较接近,与SARS-CoⅤ、MERS-CoV同为β属冠状病毒。目前临床上常用的抗病毒药物,包括神经氨酸酶抑制剂(奥司他韦、帕拉米韦、扎那米韦等)、更昔洛韦、阿昔洛韦、利巴韦林等药物对2019-nCoV均无效,不建议临床应用。目前研究证实可能有效的药物包括:瑞德西韦、洛匹那韦/利托那韦、洛匹那韦/利托那韦联合干扰素-β、恢复期血浆、单克隆抗体。但这些药物在2019-nCoV肺炎患者中的疗效和安全性有待进一步临床实验证实。.

Keywords: 2019 novel coronavirus; Antiviral therapy; Infection.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • COVID-19
  • China
  • Coronavirus Infections / drug therapy*
  • Cytochrome P-450 CYP3A Inhibitors / therapeutic use
  • Humans
  • Interferon-beta
  • Lopinavir / therapeutic use
  • Middle East Respiratory Syndrome Coronavirus
  • Pneumonia, Viral / drug therapy*
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / drug therapy

Substances

  • Antibodies, Monoclonal
  • Antiviral Agents
  • Cytochrome P-450 CYP3A Inhibitors
  • Lopinavir
  • Interferon-beta
  • Ritonavir

Supplementary concepts

  • COVID-19 drug treatment